Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Actual. osteol ; 12(2): 107-125, 2016. tab
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1372377

ABSTRACT

La osteoporosis inducida por glucocorticoides (OIC) es la causa más común de osteoporosis secundaria. La pérdida ósea se produce en forma temprana, en los primeros meses siguientes a la introducción de los glucocorticoides (GC), dependiendo de la dosis diaria. La patogénesis es multifactorial y el principal efecto deletéreo es la inhibición de la formación ósea. Los GC inducen fracturas por fragilidad ósea, especialmente en la columna vertebral, y esto genera incapacidad funcional. En los últimos años se han publicado algunas guías internacionales elaboradas por consenso para la prevención y el tratamiento de la OIC. La Sociedad Argentina de Osteoporosis designó a un grupo de trabajo para elaborar una guía propia y actualizada para el diagnóstico, la prevención y el tratamiento de la OIC (GE-OIC-SAO). (AU)


Glucocorticoid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis. It occurs early, with rapid bone loss in the first few weeks after the initiation of the treatment, with a rate that is dependent mainly on the daily dose. While the pathogenesis is multifactorial, the highest inhibitory effect occurs on bone formation. Glucocorticoids induce fragility fractures, especially in spine, generating functional disability. In recent years, there have been some international guidelines developed by consensus for the prevention and treatment of GIO. The Argentinean Osteoporosis Society appointed a working group to prepare a national guide updating the diagnosis, prevention and treatment of GIO. (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Osteoporosis/diagnosis , Osteoporosis/chemically induced , Osteoporosis/prevention & control , Osteoporosis/drug therapy , Osteoporosis/therapy , Glucocorticoids/adverse effects , Osteogenesis Imperfecta/chemically induced , Osteoporosis/physiopathology , Osteoporosis/epidemiology , Vitamin D/administration & dosage , Calcium/administration & dosage , Practice Guidelines as Topic , Teriparatide/administration & dosage , Densitometry , Diphosphonates/administration & dosage , Vertebroplasty , Osteoporotic Fractures/chemically induced , Glucocorticoids/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL